Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis

Rheumatology International

Volumn 35, Issue 4, 2015, Pages 661-668

  Krishnan, Asha ^a   Stobaugh, Derrick J ^a   Deepak, Parakkal ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Antibodies, monoclonal adverse effects; Autoimmune diseases chemically induced; Inflammatory bowel diseases chemically induced; Tumor necrosis factor alpha antagonists and inhibitors

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; CERTOLIZUMAB PEGOL; ESTROGEN; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FREEDOM OF INFORMATION ACT; HUMAN; INFLAMMATORY BOWEL DISEASE; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; PRIORITY JOURNAL; PSORIASIS; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; VASCULITIS; ADULT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, JUVENILE; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CHILD; MIDDLE AGED; PROBABILITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; ARTHRITIS, RHEUMATOID; CHILD; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROBABILITY; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84925235572     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-014-3133-9     Document Type: Article

References (29)

1. Sandborn WJ, Targan SR (2002) Biologic therapy of inflammatory bowel disease. Gastroenterology 122:1592–1608
2. Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350:2167–2179
3. García Rodríguez LA, González-Pérez A, Johansson S, Wallander MA (2005) Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther 22:309–315
4. Haraoui B, Krelenbaum M (2009) Emergence of Crohn’s disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum 39:176–181
5. Wiegering V, Morbach H, Dick A, Girschick HJ (2010) Crohn’s disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int 30:801–804
6. Ruemmele FM, Prieur AM, Talbotec C, Goulet O, Schmitz J (2004) Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr 39:203–206
7. Oh J, Arkfeld DG, Horwitz DA (2005) Development of Crohn’s disease in a patient taking etanercept. J Rheumatol 32:752–753
8. van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H et al (2011) Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 38:1441–1446
9. Dallocchio A, Canioni D, Ruemmele F, Duquesne A, Scoazec JY, Bouvier R et al (2010) Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford) 49:1694–1698
10. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G (2000) Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 95:1949–1954
11. Toussirot É, Houvenagel É, Goëb V, Fouache D, Martin A, Le Dantec P et al (2012) Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone Spine 79:457–463
12. The Adverse Event Reporting System (AERS) Older quarterly data files [homepage on the Internet]. U.S. Food and Drug Administration [updated 2013 Aug 15; cited 2014 June 20]. http://www.fda.gov/
13. Dubeau MF, Iacucci M, Beck PL, Moran GW, Kaplan GG, Ghosh S et al (2013) Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm Bowel Dis 19:445–456
14. Bernstein CN, Wajda A, Blanchard JF (2005) The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 129:827–836
15. Ha C, Magowan S, Accortt NA, Chen J, Stone CD (2009) Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol 104:1445–1451
16. Kappelman MD, Galanko JA, Porter CQ, Sandler RS (2011) Association of paediatric inflammatory bowel disease with other immune-mediated diseases. Arch Dis Child 96:1042–1046
17. Naldi L, Mercuri SR (2010) Epidemiology of comorbidities in psoriasis. Dermatol Ther 23:114–118
18. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245
19. Deepak P, Stobaugh DJ, Sherid M, Sifuentes H, Ehrenpreis ED (2013) Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther 38:388–396
20. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD et al (2001) Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121(5):1088–1094
21. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I et al (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 124(7):1774–1785
22. Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P et al (2005) Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21(3):251–258
23. Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L (2001) Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 60(2):133–139
24. Lees CW, Barrett JC, Parkes M, Satsangi J (2011) New IBD genetics: common pathways with other diseases. Gut 60:1739–1753
25. Gale EA (2009) Collateral damage: the conundrum of drug safety. Diabetologia 52:1975–1982
26. FDA Adverse Event Reporting System (FAERS) (formerly AERS) [homepage on the Internet]. U.S. Food and Drug Administration [updated 2012 Sep 10; cited 2014 June 20]. http://www.fda.gov/
27. Holden W, Orchard T, Wordsworth P (2003) Enteropathic arthritis. Rheum Dis Clin North Am 29:513–530
28. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppälä K (1994) High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 37:23–31
29. Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22:847–861